Molecular microbiologists from the Keck School of Medicine of USC have discovered that mice lacking a specific component of the immune system are completely resistant to sepsis, a potentially fatal complication of infection. The discovery suggests that blocking this immune system component may help reduce inflammation in human autoimmune and hyper-inflammatory diseases such as rheumatoid arthritis and Type 2 diabetes.
The study was published online on June 23 in The Journal of Experimental Medicine, a leading peer-reviewed scientific journal in research medicine and immunology.
The immune system is the body’s first line of defense against infection. The system, however, can also injure the body if it is not turned off after the infection is destroyed, or if it is turned on when there is no infection at all. Scientists do not yet fully understand how the immune response is turned on and off and continue to study it in hopes of harnessing its power to cure disease.
In this study, scientists have found that a component of the system, HOIL-1L, is necessary for formation of the NLRP3-ASC inflammasome signaling complex.
“This regulatory mechanism is critical in vivo, where we find that mice lacking HOIL-1L are completely resistant to sepsis, which is a lethal inflammation model of human sepsis,” said Mary Rodgers, USC postdoctoral fellow and the study’s first author. “Our results suggest that blocking the activity of HOIL-1L could be a new therapeutic strategy for reducing inflammation in disease.”
Led by Jae Jung, professor and chair of the Department of Molecular Microbiology and Immunology at the Keck School of Medicine, the research team included scientists from the University of North Carolina at Chapel Hill and Kyoto University in Japan. USC study co-authors also include James Bowman; Nicole Orazio, Mude Shi, Qiming Liang, Rina Amatya and Thomas Kelly. The work was partly supported by the National Institutes of Health (grant numbers 1F32AI096698, CA180779, CA082057, CA31363, CA115284, AI073099, AI083025, HL110609, CA156330, AI029564), the Global Research Lab, the Hastings Foundation and The Fletcher Jones Foundation.